Check the terms behind the claim

Which approval is being claimed

Approval, a license and registration answer different questions.

The Food and Drug Administration, called FDA, is the federal medicine regulator.

A business’s registration with FDA confers no approval on its drugs or the business itself. The federal record checked September 26, 2026 also says FDA does not approve health care practices.

A compounded medicine remains outside FDA approval even when a pharmacy is licensed, as of September 26, 2026.

In compounding, that medicine is prepared around a particular person’s needs by a doctor or pharmacist. Ask which finished product is being discussed and which evidence supports that product and use. A statement about its ingredient is not the same answer.

As of September 26, 2026, a National Drug Code, an identifying number in a federal directory, does not establish that FDA has approved the product.

What changed about compounded copies

Ask for the reason a made-to-order version is being proposed.

As of September 26, 2026, federal rules restrict routine compounding of medicines that are essentially copies of commercially available approved drugs.

Under that pharmacy rule, the person writing your prescription must identify a change that matters for your own medical needs. The price alone cannot count as that difference.

FDA describes needs such as being unable to swallow a tablet or being allergic to a dye in a medicine.

Ask which change addresses your own need; an example does not settle whether a particular copy is allowed.

In the record checked September 26, 2026, semaglutide injection was off FDA’s national shortage list. Tirzepatide was off the list too. Local stock trouble does not put a drug back on that federal list.

These are dated findings. Ask for the current basis for the specific preparation rather than relying on a headline about an earlier shortage. The question is about the medicine proposed for you, not whether compounding exists in general.

Claims that deserve a pause

Ask for a concrete answer before paying.

In the federal record checked September 26, 2026, a prescription drug dispensed without a valid prescription violates the prescription requirement.

FDA’s guidance checked September 26, 2026 calls these claims about a compounded drug false or misleading: FDA-approved, a generic of an approved medicine, or proven to give the same results.

For semaglutide (Ozempic, Wegovy), there was no approved generic available for U.S. sale on November 3, 2026. The same was true for tirzepatide (Mounjaro, Zepbound). A compounded product is not FDA-approved.

FDA reported false labeling for compounded versions of semaglutide and tirzepatide in the record checked September 26, 2026. A label could name a fictitious pharmacy, or a real pharmacy that did not prepare that item.

If a service cannot name the pharmacy, leave that question open. Match the pharmacy and the person assessing you to the public records rather than treating a badge on a website as the answer.

A bulk ingredient is the raw active substance used to make a medicine. A nomination is a request to add an ingredient to FDA’s list for pharmacy compounding. Withdrawn means the group making the request took it back.

BPC-157 is a peptide ingredient proposed for compounded medicines. FDA’s ingredient page lists BPC-157 under withdrawn requests. April 22, 2026 is the date FDA gives for how current that page is. FDA still lists safety concerns. The withdrawal is not FDA approval.

The U.S. Department of Health and Human Services (HHS) announced a separate draft policy on October 30, 2026. It describes when HHS intends to hold off on enforcement for BPC-157, KPV, epitalon, semax, TB-500 and MOTS-c. It applies to state-licensed pharmacies and physicians making a single-ingredient medicine for an individual patient’s prescription, with every policy condition met. Blends and 503B outsourcing facilities, which make batches of compounded drugs, are excluded. This nonbinding draft is not FDA approval; none of those six appears on FDA’s 503A bulks list for pharmacy compounding.

FDA flags possible immune reactions: your body may treat an injected peptide as an invader. It also flags impurities. The safety information checked September 26, 2026 is too limited for FDA to say whether BPC-157 would cause harm.

FDA gives no withdrawal date for each ingredient, so the April 22, 2026 page date cannot tell you when the BPC-157 request was taken back.

A label might say “for research purposes”; another might say “not for human consumption.” Neither means approval for treatment. FDA’s warning checked September 26, 2026 says such products sold to consumers for treatment have unknown quality and may be harmful.

Where the dates and figures come from

Read the terms attached to a number.

Before comparing a cash offer with an insured copay, check what each amount covers and which terms apply to you. Keep the exact product, supply period and payment route with the number.

The national price examples here come from terms recorded September 26, 2026, while the Florida checks use the state record dated September 28, 2026.

An offer can change after it is recorded. Ask for the terms in force when the prescription is being considered, including any end date or refill condition.

Where to raise a concern

Keep the written quote and the names involved.

As of September 28, 2026, Florida’s Department of Health accepts written, signed complaints about licensed practitioners and pharmacies, but does not handle ordinary billing or refund disputes.

Florida’s Attorney General accepts consumer complaints about deceptive or unfair business practices; information submitted is generally public record, as described in the September 28, 2026 record.

For the next care conversation, take the unanswered questions rather than a conclusion drawn from a sales page. Ask the clinician to address the proposed product, the evidence for its use and the plan for questions after the visit.